ALK-prick N - 302 Ragweed (Ambrosia) - 1:100 G/V - Lösung für den Pricktest
Sponsors
ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH
Conditions
Moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen
for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA)
guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen
for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA)
guideline
Phase 2
Phase II-III study to assess the efficacy and safety of
sublingual immunotherapy in patients suffering from birch
pollen allergy
CompletedCTIS2023-505567-37-00
Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22
Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
CompletedCTIS2023-505880-35-00
Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15